Aehr Test Systems (AEHR) Q1 2027 Earnings Call Transcript

Aehr Test Systems reported record fiscal Q1 2027 revenue of $33 million, up 200% year over year and 75% sequentially, with non-GAAP gross margin rising 11 percentage points to 48.5%. Bookings were $46.7 million and effective backlog reached $109.3 million as of November 1; management raised FY2027 revenue guidance to $150 million from a prior range of $130 million to $150 million and expects non-GAAP net income of at least 20% of revenue. Growth is being driven by AI semiconductor burn-in demand, while a major AI-processor evaluation is planned for installation in Taiwan in early calendar 2027 and remains subject to validation and a production decision. Management also cited slower-than-expected NAND opportunities and said gross margin may be lower in Q2 as Sonoma system shipments increase.

Analysis

The important shift is from selling equipment into AI ramps to potentially embedding Aehr in the reliability-screening workflow. If wafer-level burn-in proves production-worthy at the Taiwan evaluation, it could both unlock additional FOX demand and encourage customers to screen costly dies before advanced packaging—where a late failure destroys more value. That is a meaningful adoption catalyst, not yet a booked revenue stream: the high-volume decision follows installation and validation in early 2027, and management’s per-unit revenue potential is a scenario, not a forecast.

Near term, the raised outlook and backlog support the execution case, but backlog should not be treated as revenue certainty. Orders, delivery schedules, and customer qualification can shift; rising inventory and operating cash use show the working-capital cost of preparing for ramps. Sonoma contract manufacturing expands stated capacity, but supplier availability, assembly throughput, and customer acceptance remain gating variables. Consumables add repeat revenue and potential switching costs, though device-specific replacements and product mix make this less annuity-like than the headline mix implies.

Over 1–3 months, watch whether shipments convert backlog without margin erosion; management expects quarterly gross-margin variation. The key 6–18 month test is the Taiwan evaluation and conversion to high-volume orders. Teradyne (TER) and Cohu (COHU) are adjacent test-market exposures, but the call describes system-level test as a different insertion; this is not evidence of near-term share loss. Contrarian risk: diversification across more than a dozen potential programs may sound like customer diversification, but realized revenue still appears reliant on a small number of production ramps. No valuation or post-call price data is supplied, so avoid assuming the strong results make AEHR cheap.

Key Decisions for Investors

• AEHR: Consider a staged, tactical long rather than chasing an earnings gap. Add only if subsequent results show backlog converting into shipments and full-year guidance holding; keep exposure modest until customer-level revenue concentration and valuation are verified.
• Track the Taiwan FOX evaluation as the main catalyst: installation is planned for early 2027, with production decisions expected after validation. A delayed installation, failed production metrics, or no follow-on order would weaken the structural-growth thesis.
• Monitor quarterly gross margin, inventory, and operating cash flow together. Margin deterioration beyond mix-related variation, inventory rising faster than deliverable demand, or a guidance cut would falsify the near-term execution case.
• Do not short TER or COHU on this call alone: their cited system-level test products are adjacent rather than demonstrated direct substitutes. Revisit only with evidence of competitive displacement or a clearly mispriced relative valuation.